Beijing Friendship Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1952-01-01

Employees: 1K

Market Cap: -

Website: https://www.bfh.com.cn

Clinical Trials

Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer

Conditions: Colorectal Neoplasms

Interventions: Combination Product: long course radiotherapy + capecitabine + PD-1 monoclonal antibody

First Posted Date: 2022-05-10

Last Posted Date: 2022-05-10

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 30

Registration Number: NCT05368051

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

Selinexol Combined With Dexamethasone in the Treatment of CAEBV

Phase 3

Not yet recruiting

Conditions: CAEBV

Interventions: Drug: Selinexol and Dexamethasone

First Posted Date: 2022-04-26

Last Posted Date: 2022-04-26

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 6

Registration Number: NCT05347381

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China

Relationship Between Perioperative Related Factors and Inflammatory Markers and Postoperative Delirium in Elderly Patients With Non-cardiac Major Surgery

Not yet recruiting

Conditions: Preoperative Sleep Disorder
Inflammatory Reaction
Preoperative Anxiety
Postoperative Delirium

First Posted Date: 2022-04-22

Last Posted Date: 2022-04-22

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 400

Registration Number: NCT05341531

Analysis of Influencing Factors of Hypotension in Diabetic Patients Undergoing Dialysis

Conditions: Hemodialysis
Diabetes

Interventions: Combination Product: This is an observational study

First Posted Date: 2022-04-13

Last Posted Date: 2022-04-13

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 180

Registration Number: NCT05325892

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

Zanubrutinib for HLH

Phase 3

Completed

Conditions: HLH

Interventions: Drug: Zanubrutinib

First Posted Date: 2022-04-11

Last Posted Date: 2024-04-11

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 16

Registration Number: NCT05320575

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China

Subcutaneous Closed-Suction Drainage Affects Surgical Wounds Healing in Lower Gastrointestinal Open Surgery: a Randomized Controlled Study

Phase 2

Conditions: All Diseases That Require Gastrointestinal Open Surgery

Interventions: Device: Subcutaneous closed-suction drainage device

First Posted Date: 2022-04-08

Last Posted Date: 2022-04-08

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 228

Registration Number: NCT05318430

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China

L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH

Phase 3

Not yet recruiting

Conditions: Hemophagocytic Lymphohistiocytosis

Interventions: Drug: L-DEP and PD-1 antibody

First Posted Date: 2022-04-07

Last Posted Date: 2022-04-26

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 50

Registration Number: NCT05315336

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China

Clinical Analysis of a Risk-graded and Comprehensive Intervention for Early-childhood-caries

Not Applicable

Recruiting

Conditions: Early Childhood Caries

Interventions: Combination Product: Comprehensive prevention and treatment
Combination Product: Routine prevention

First Posted Date: 2022-03-02

Last Posted Date: 2022-07-21

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 480

Registration Number: NCT05260216

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV

Not Applicable

Conditions: PTLD
HLH
CAEBV

Interventions: Drug: low-dose CD20 monoclonal antibody injection

First Posted Date: 2022-02-28

Last Posted Date: 2022-02-28

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 20

Registration Number: NCT05258136

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Combination Product: Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)

First Posted Date: 2022-02-18

Last Posted Date: 2024-01-10

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 186

Registration Number: NCT05245474

Locations: 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China

and more 5 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy